Research progress on the effect of osteoporosis treatment drugs on ocular diseases
10.3760/cma.j.cn115989-20230127-00028
- VernacularTitle:骨质疏松症治疗药物应用对眼部疾病影响的研究进展
- Author:
Haiyu LIU
1
;
Suyan LI
Author Information
1. 徐州医科大学第二临床医学院眼视光医学系，徐州 221004
- Keywords:
Osteoporosis;
Estrogen;
Vitamin D;
Bisphosphonate;
Age-related macular degeneration
- From:
Chinese Journal of Experimental Ophthalmology
2024;42(5):491-496
- CountryChina
- Language:Chinese
-
Abstract:
Osteoporosis (OP) is a systemic disease characterized by decreased bone mass, increased bone fragility due to damage to the microstructure of bone tissue, and susceptibility to fractures.At present, it mainly relies on pharmacologic treatment.Because the occurrence of OP and some eye diseases are associated with a series of age-related pathological mechanisms, and OP therapeutic drugs also have anti-non-infectious inflammation, antioxidant, anti-apoptosis, and sex hormone-regulating effects, there is a certain correlation with the pathogenesis of some ophthalmic diseases, and thus affect the onset and progression of eye diseases.The application of OP therapeutic drugs such as vitamin D and its derivatives, estrogen, bisphosphonates, and desuximab may increase the risk of age-related macular degeneration, dry eye, and ocular inflammation, and may also play a preventive role in some eye diseases such as dry eye, cataract, glaucoma, and choroidal neovascularization.Therefore, when OP therapeutic drugs are used clinically, the changes of related eye diseases should be regularly monitored.This article reviews the research on the effects of OP therapeutic drugs on eye diseases.
